ABOUT THE EVENT
Date: Thursday, February 26, 2026 9–10am PST
Event Location: Virtual
Antibody-drug conjugates (ADCs) represent a powerful therapeutic modality for solid tumors and hematological malignancies. However, their development is often challenged by limited translational insights, narrow therapeutic windows, and the difficulty in differentiating new candidates from existing therapies.
This webinar will showcase how practical in vitro assay design can address key challenges for ADCs in oncology. We will introduce a set of bioassays, including cytotoxicity, bystander killing, internalization, and serum stability, to evaluate drug MOA, specificity, and potency. Real-world case studies will highlight how these data-driven approaches support candidate selection, enable clear differentiation of new candidates, and improve prediction of in vivo performance.
In this webinar, you will learn how to:
- Design in vitro models and select appropriate cell lines to differentiate new ADC candidates
- Apply core assays to define and optimize the therapeutic window
- Leverage advanced analytical tools (high-content imaging, flow cytometry, IncuCyte, etc.) to generate robust, quantitative data
- Turn assay results into practical insights to bridge discovery and translational studies
Speaker:
Zhuo Mao, Ph.D., Director, CRO Services
